Trial Profile
A Phase 2, Prospective, Multi-Center, Randomized, Two-Arm, Active Controlled, Double-Blind Study to Evaluate the Safety, Tolerability and Immunogenicity of Serum Institute of India 10-valent Pneumococcal Conjugate Vaccine (SIILPCV10) in Healthy Indian PCV-Naive Toddlers (12 to 15 months)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Jul 2019
Price :
$35
*
At a glance
- Drugs SIILPCV10 (Primary) ; Pneumococcal 13-valent CRM197 vaccine conjugate
- Indications Bacteraemia; Meningitis; Otitis; Pneumococcal infections; Pneumonia; Sepsis; Streptococcal infections
- Focus Adverse reactions
- Sponsors Serum Institute of India
- 26 Mar 2019 Status changed from not yet recruiting to completed.
- 26 Aug 2016 New trial record